1. Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling.
- Author
-
Li, Ning, Sun, Ya-Jie, Huang, Li-Yun, Li, Rong-Rong, Zhang, Jun-Sheng, Qiu, Ai-Hua, Wang, Jing, and Yang, Lu
- Abstract
Acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) frequently emerges, and CDK4/6i-containing therapies in triple-negative breast cancer (TNBC) remain to be determined. RNA-sequencing, cell viability analysis, immunoblotting, siRNA transfection et al. were used to investigate and verify the resistance mechanism. BALB/c nude mice xenograft models and spontaneous MMTV-PyMT models were used to explore in vivo efficacy. The mTOR pathway was activated in acquired CDK4/6i-resistant cells and inhibition of mTORC1 restored the sensitivity. While fasting-mimicking diet (FMD) enhances the activity of anticancer agents by inhibiting the mTORC1 signaling, we assessed FMD and found that FMD restored the sensitivity of CDK4/6i-resistant cells to abemaciclib and potentiated the anti-tumor activity of CDK4/6i in TNBC. The anti-tumor effects of FMD and/or CDK4/6i were accompanied by the downregulation of S6 phosphorylation. FMD cooperated with CDK4/6i to suppress the levels of IGF1 and RAS. The combination of FMD and abemaciclib also led to a potent inhibition of tumor growth in spontaneous transgenic MMTV-PyMT mouse models. Our data demonstrate that FMD overcomes resistance and potentiates the anti-tumor effect of CDK4/6i by inhibiting mTORC1 signaling via lowering the levels of IGF1 and RAS, providing the rationale for clinical investigation of a potential FMD-CDK4/6i strategy in breast cancer. • mTORC1 activation is a key mechanism governing CDK4/6i-resistance in breast cancer. • FMD reversed CDK4/6i-resistance by suppressing the mTORC1 pathway. • CDK4/6i-resistance can be reversed by FMD through lowering the levels of IGF1 and RAS. • FMD cooperated with CDK4/6i in a transgenic MMTV-PyMT mouse model with favorable feasibility. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF